Chinese english Germany Japanese Korea

3-[2-[(1S,5S,7S)-7-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl]-1H-quinazoline-2,4-dione

3-[2-[(1S,5S,7S)-7-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl]-1H-quinazoline-2,4-dione Struktur
208661-17-0
CAS-Nr.
208661-17-0
Englisch Name:
3-[2-[(1S,5S,7S)-7-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl]-1H-quinazoline-2,4-dione
Synonyma:
Lu 111995;Belaperidone;3-[2-[(1S,5S,7S)-7-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl]-1H-quinazoline-2,4-dione;2,4(1H,3H)-Quinazolinedione, 3-(2-((1S,5R,6S)-6-(4-fluorophenyl)-3-azabicyclo(3.2.0)hept-3-yl)ethyl)-
CBNumber:
CB81876495
Summenformel:
C22H22FN3O2
Molgewicht:
379.43
MOL-Datei:
208661-17-0.mol
Request For Quotation

3-[2-[(1S,5S,7S)-7-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl]-1H-quinazoline-2,4-dione Eigenschaften

Dichte
1.287±0.06 g/cm3(Predicted)
pka
12.84±0.20(Predicted)

Sicherheit

3-[2-[(1S,5S,7S)-7-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl]-1H-quinazoline-2,4-dione Chemische Eigenschaften,Einsatz,Produktion Methoden

3-[2-[(1S,5S,7S)-7-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl]-1H-quinazoline-2,4-dione Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

3-[2-[(1S,5S,7S)-7-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl]-1H-quinazoline-2,4-dione Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 3)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
TargetMol Chemicals Inc. 		+1-781-999-5354 +1-00000000000
 marketing@targetmol.com United States 19892 58
TargetMol Chemicals Inc. 4008200310
 marketing@tsbiochem.com China 24017 58
Suzhou Meishi Biotechnology Co., Ltd. 1173954148q
 meishipharma@126.com China 20035 58
  • 3-[2-[(1S,5S,7S)-7-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl]-1H-quinazoline-2,4-dione
  • 2,4(1H,3H)-Quinazolinedione, 3-(2-((1S,5R,6S)-6-(4-fluorophenyl)-3-azabicyclo(3.2.0)hept-3-yl)ethyl)-
  • Belaperidone
  • Lu 111995
  • 208661-17-0
Copyright 2019 © ChemicalBook. All rights reserved